June 18, 2011

Polyfunctional Cytomegalovirus-Specific Immunity in Lung Transplant Recipients Receiving Valganciclovir Prophylaxis


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Extending the duration of CMV prophylaxis in lung transplant patients at risk of CMV can prevent disease, but a concern is potential prevention or reduction of CMV-specific immunity.  In this pilot study, development of CMV-specific immunity in recipients receiving extended antiviral prophylaxis with valganciclovirfor a median of 6 months post-transplant was compared to recipients not on prophylaxis and to healthy non-transplant controls.  Measuring polyfunctional cytokine production, the study demonstrated CMV-specific immunity in CMV seropositive lung transplant recipients onvalganciclovir, suggesting that valganciclovir does not impair the maintenance of CMV-specific immunity in lung transplantation.

Lung Transplantation, Transplant Infectious Disease

Tags: , ,